Defining pathological variables to predict biochemical failure in patients with positive surgical margins at radical prostatectomy: implications for adjuvant radiotherapy
Matthew J. Resnick(Vanderbilt University Medical Center), S. Bruce Malkowicz(Hospital of the University of Pennsylvania), Meredith Bergey(Brandeis University), Alan J. Wein(University of Miami), Thomas J. Guzzo(Hospital of the University of Pennsylvania), Laurie Magerfleisch(Hospital of the University of Pennsylvania), John E. Tomaszewski(University of Pennsylvania), Seema S. Sonnad(University of Pennsylvania), Benjamin M. Brucker(University of Pennsylvania), Daniel Canter(Ochsner Medical Center)
Cited by 31
Related Papers
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
|European Urology|2015|688
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Renal Carcinomas With the t(6;11)(p21;q12)
|The American Journal of Surgical Pathology|2005|291